Continuing Education Council
STO’s Education Council works with the Executive Director and Director of Programs and Compliance to set the direction and vision for STO’s CE program, determine practice gaps and programming needs, recommend program improvements, participate in the review of program planning, development, content and mitigation, and assist in an annual review of the CE program.
Ann Murphy, PhD, is the Executive Director of the Society for Translational Oncology (STO). She has served on the board of STO for over two decades, working closely with other board members to identify the needs of oncology and hematology practitioners and steering STO to create and implement strategies and programs to enhance care for cancer patients and others with weakened immune systems.
Ann is also the President and CEO of AlphaMed Press. Under Ann’s leadership, AlphaMed Press founded three internationally renowned peer-reviewed journals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines: THE ONCOLOGIST® (1996), devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care; STEM CELLS® (1983), the world's first journal devoted to this fast-paced field of research; and STEM CELLS TRANSLATIONAL MEDICINE® (2011), bridging stem cell research and clinical trials. In January 2022, these three journals were entrusted, via acquisition, to Oxford University Press (OUP).
Ann’s community and philanthropic board engagements include membership on University of North Carolina-Chapel Hill Board of Visitors.
Dr. Jayne Gurtler is a founding partner of Metairie Oncologist. She is a graduate of Newcomb College, Tulane University, and Tulane University School of Medicine. She completed her Internal Medicine Residency and Hematology/Oncology Fellowship training at Ochsner Foundation Hospital and followed this with a fellowship in Developmental Therapeutics from MD Anderson Hospital and Tumor Institute.
Dr. Gurtler is a Fellow of the American College of Physicians-American Society of Internal Medicine and an active member of the American Society of Clinical Oncology and Jefferson Parish Medical Society.
Dr. Gurtler serves on the editorial board of The Oncologist, a peer-reviewed academic publication of The Society for Translational Oncology.
Dr. Gurtler served on the faculty of Xavier University School of Pharmacy. A board-certified oncologist, she has conducted oncology research for more than 40 years and has over 20 publications in the last ten years. Every day, Dr. Gurtler strives to help her patients live fuller lives.
Hyman B. Muss, MD, is an experienced clinician-scientist, the Mary Jones Hudson Distinguished Professor of Geriatric Oncology at the University of North Carolina School of Medicine, and the Director of the Geriatric Oncology Program at the UNC Lineberger Comprehensive Cancer Center Program.
As an internationally recognized leader in education and research focused on cancer in older patients, Dr. Muss’s professional interests center on the research and care of older women with breast cancer, breast cancer survivorship, and long-term toxicity of treatment.
After working with his previous UNC colleague, Dr. Ned Sharpless, Dr. Muss is investigating the role of biomarkers of aging and their potential role as predictors of toxicity and survival. In addition to developing and serving as the PI of multiple clinical and translational trials, he was the lead author of the NCI-sponsored intergroup trial that compared standard care with oral chemotherapy in older women with early-stage breast cancer, which for the first time, showed the value of chemotherapy in this older population.
He serves as the mentor for medical students, residents, junior faculty, and more recently Geriatric Oncology fellows. He previously co-chaired the Alliance Committee on Cancer in Older Adults. He has been co-chair of the Breast Committee for the CALGB, Chair and a member of the board of Directors of the American Board of Internal Medicine, and a member of the Board of Directors of the American Society of Clinical Oncology (ASCO) and the ASCO Foundation. He was awarded the B.J. Kennedy Award in Geriatric Oncology by ASCO, the Susan G. Komen for the Cure Brinker Award for Scientific Distinction in Clinical Research, and an honorary Doctor of Science Degree from his alma mater, Lafayette College. He served in the U.S. Army in Vietnam where he was awarded the Bronze Star medal.
Amy has been affiliated with the University of North Carolina (UNC) breast oncology group since May 2011. Prior to joining the breast group to work with Dr Hyman Muss and Dr Lisa Carey, Amy worked with cancer patients, administering chemotherapy.
Amy moved from Tennessee to join UNC a month after the opening of the new cancer hospital. During her time at UNC, Amy continued her nursing education by obtaining her BSN and MSN from UNC-Wilmington. In 2013, she was awarded the UNC School of Medicine Nursing Recognition Award.
Aimee Faso, PharmD, CPP, BCOP, is a clinical pharmacist practitioner in breast oncology at the North Carolina Cancer Hospital in Chapel Hill, NC. She received her PharmD degree from the University of Florida in 2003 and completed her residency at the Dartmouth Hitchcock Medical Center in 2004.
Aimee joined the University of North Carolina (UNC) as an oncology pharmacist in 2008 and has been working with the UNC breast oncology team to provide patient education and care since 2014.
Aimee is involved with teaching including precepting pharmacy students and residents in the discipline of oncology pharmacy. She serves as an adjunct faculty member at the UNC Eshelman School of Pharmacy and is a Clinical Associate Professor at the UNC School of Nursing.
Chuck is retired from the National Institutes of Health and now lives in Strafford, Vermont. At the NIH he was Deputy Director of the Office of Medical Applications of Research that sponsored medical Consensus Development Conferences and offered CME credits on-line. Chuck was also Director of the NIH Office of Program Evaluation with a special interest in research training support. In retirement, he serves on the Institutional Review Boards of Dartmouth College and Geisel School of Medicine. He is also on the boards of the Vermont Institute of Natural Science, ValleyNet (providing broadband internet in the Upper Valley of VT/NH), and Equal Access to Broadband (providing subsidies for broadband to under-resourced households).
Chuck holds an AB from Dartmouth College and PhD from the University of North Carolina at Chapel Hill.
Dr. Bruce Chabner serves as the Clinical Director Emeritus for the Massachusetts General Hospital Cancer Center and a Professor of Medicine at Harvard Medical School.
His main fields of research focus on the biochemistry and pharmacology of folate antagonists, experimental therapeutics, and clinical trial design.
He has served as the Chief of Hematology and Oncology at the MGH from 1995 to 2007, the Clinical Director of the MGH Cancer Center from 1995 to 2010, and Associate Director of Clinical Science at Dana Farber/Harvard Cancer Center (2000-2010). Prior to accepting his position at MGH, he served in the US Public Health Service at the National Institutes of Health from 1971 to 1995 and held the position of Director of the Division of Cancer Treatment of the National Cancer Institute from 1982 to 1995, retiring as an Assistant Surgeon General in 1995.
Dr. Chabner received his B.A., summa cum laude, from Yale College (1961) and an M.D., cum laude, from Harvard Medical School (1965).
He has authored and edited the standard text, Principles and Practice of Cancer Chemotherapy and Biological Response Modifiers, now in its sixth edition, and the Harrison’s Manual of Oncology, now in its 2nd edition. Dr. Chabner has contributed to and served as editor of the Goodman and Gilman textbook of Pharmacology and has authored chapters for numerous other textbooks of internal medicine, hematology, oncology and pharmacology.
Over the years, Dr. Chabner has received awards including Phi Beta Kappa, Alpha Omega Alpha, the Public Health Service's Distinguished Service Medal, the Karnofsky Award of the American Society for Clinical Oncology and the Bruce F. Cain Award for Drug Development of the American Association for Cancer Research. In 2006, he was the first recipient of the Bob Pinedo Award for Contributions to Improvement in the Care of Cancer Patients.
Dr. Chabner is founding editor-in-chief for The Oncologist and serves on the executive advisory boards for some of the industry’s leading innovators in drug development. In 2006, Dr. Chabner received a presidential appointment to the National Cancer Advisory Board at the National Cancer Institute and chaired the NCAB from (2010-2012). In 2020, he was selected to be the Inaugural speaker for the FDA series, “Icons of Oncology”’.
Privacy Policy | Terms of Use | Contact Us
Society for Translational Oncology (STO) is a 501(c)(3) not-for-profit organization.
Copyright © 2023. All rights reserved.